[Featured Stock] Humasis, Increased Diagnostic Demand Due to COVID Delta Variant Spread... Expansion of Overseas Market Access

[Asia Economy Reporter Hyungsoo Park] Humasis is showing strong performance day after day. Concerns have arisen that the spread of the 'Delta variant,' which is more transmissible than COVID-19, will intensify again as it rapidly spreads to countries around the world, seemingly impacting the stock price.

As of 1:47 PM on the 24th, Humasis is trading at 18,950 KRW, up 12.13% from the previous day.

On this day, the on-site rapid testing specialist company Humasis announced that it has obtained sales approval in Vietnam for its COVID-19 antigen diagnostic kit.

Humasis conducted clinical evaluations locally in Vietnam to obtain sales approval for its COVID-19 antigen diagnostic kit, ‘Humasis COVID-19 Ag Test.’ The product’s excellent performance was recognized, leading to the approval. It can confirm positive and negative results within 15 minutes from a single specimen collection, and it also received official domestic approval for use in March.

Currently, Vietnam has seen a rapid increase in cases over the past month due to the resurgence of the COVID-19 virus. This has raised concerns, including impacts on domestic companies operating large-scale production facilities locally.

Humasis plans to expand distribution networks and sales through its local subsidiary, Humasis VINA, in Vietnam.

A Humasis official stated, "Due to the recent rapid resurgence of COVID-19, demand for diagnostic kits is increasing again locally in Vietnam. Along with the antigen diagnostic kit approval, we are also undergoing procedures for sales approval of personal test kits and antibody diagnostic kits, and we expect approval soon."

On the 10th, Humasis donated 3,000 COVID-19 antigen diagnostic tests to the local health department in Vietnam.

This content was produced with the assistance of AI translation services.